Search form
Search
contact us
Navigation
home
boards
job ratings
cp wire
medtech news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» vamorolone
vamorolone
Duchenne muscular dystrophy: major trials and events to watch in 2023
Duchenne muscular dystrophy: major trials and events to watch in 2023
Clinical Trials Arena
DMD
Duchenne Muscular Dystrophy
clinical trials
gene therapy
FDA
Sarepta Therapeutics
SRP-9001
FibroGen
pamrevlumab
Capricor
CAP-1002
Santhera
ReveraGen
vamorolone
Flag link:
Duchenne muscular dystrophy’s progress so far in 2023
Duchenne muscular dystrophy’s progress so far in 2023
Clinical Trials Arena
Duchenne Muscular Dystrophy
DMD
Santhera Pharmaceuticals
ReveraGen
vamorolone
Regenxbio
RGX-202
Flag link:
FDA accepts Santhera, ReveraGen’s vamorolone NDA to treat DMD
FDA accepts Santhera, ReveraGen’s vamorolone NDA to treat DMD
Pharmaceutical Business Review
Santhera Pharmaceuticals
ReveraGen
vamorolone
Duchenne Muscular Dystrophy
FDA
Flag link:
Santhera seeks speedy FDA review of Duchenne drug vamorolone
Santhera seeks speedy FDA review of Duchenne drug vamorolone
Pharmaphorum
Santhera
Duchenne Muscular Dystrophy
vamorolone
FDA
Flag link:
Buoyed by new data, Santhera preps filing for DMD drug vamorolone
Buoyed by new data, Santhera preps filing for DMD drug vamorolone
Pharmaforum
Santhera
DMD
Duchenne Muscular Dystrophy
idebenone
vamorolone
FDA
Flag link:
Months after axing a Duchenne program and laying off dozens, Santhera claims a win there with a different program
Months after axing a Duchenne program and laying off dozens, Santhera claims a win there with a different program
Endpoints
Santhera Pharmaceuticals
Duchenne Muscular Dystrophy
vamorolone
clinical trials
Flag link:
Three Biotechs Shutter Clinical Programs After Futility Analysis or Failed Trials
Three Biotechs Shutter Clinical Programs After Futility Analysis or Failed Trials
BioSpace
Jounce Therapeutics
vopratelimab
Santhera
vamorolone
Puldysa
Aurinia Pharmaceuticals
FOS
Flag link:
Santhera axes half its employees and sees CMO depart after PhIII DMD fail
Santhera axes half its employees and sees CMO depart after PhIII DMD fail
Endpoints
Santhera
reorganization
Duchenne Muscular Dystrophy
vamorolone
layoffs
Flag link:
Santhera bags DMD drug in 3-way deal with Idorsia and ReveraGen
Santhera bags DMD drug in 3-way deal with Idorsia and ReveraGen
Fierce Biotech
Santhera
vamorolone
Duchenne Muscular Dystrophy
Idorsia
ReveraGen
Flag link:
Santhera's Duchenne effort gets a boost on positive PhIIa for alternative steroid vamorolone — though there's a lot left to prove
Santhera's Duchenne effort gets a boost on positive PhIIa for alternative steroid vamorolone — though there's a lot left to prove
Endpoints
Santhera
Duchenne Muscular Dystrophy
clinical trials
vamorolone
RaveraGen
Flag link: